Table 2 Predictive and prognostic scores developed by different consortia

Prognostic scores

CLIF-C ACLFs

Acutely decompensated cirrhosis

CLIF‐OFs (TB, creatinine, use of RRT, HE, endotracheal intubation for HE, INR, MAP, Use of vasopressors, PaO2, SpO2, FiO2), age, WBC

10 × [0.33 × CLIF-OFs) + 0.04 × age + 0.63 × ln (WBC, 10⁹/L) − 2]

Individual estimates of mortality

COSSH-ACLFs

Acute deterioration of HBV-related chronic liver disease

HBV-SOFAs (creatinine, HE, MAP, Use of vasopressors, PaO2, SpO2, FiO2), INR, age, TB

0.741 × INR + 0.523 × HBV-SOFAs + 0.026 × age + 0.003 × TB (μmol/L)

/

COSSH-ACLF IIs

Acute deterioration of HBV-related chronic liver disease

INR, HE, neutrophil, TB, serum urea, age

1.649 × ln(INR) + 0.457 × HE score (0/I-II/III-IV: 1/2/3 points) + 0.425 × ln(neutrophil, 10⁹/L) + 0.396 × ln(TB, umol/L) + 0.576 × ln(serum urea, mmol/L) + 0.033 × age

Individual estimates of mortality;

Risk stratification: 28-/90-day Mortality:

Low-risk (< 7.4): 8%/19%;

Intermediate-risk (7.4–8.4): 50%/66%;

High-risk (≥ 8.4): 76%/88%

AARC-ACLFs

Acute deterioration of chronic liver disease

TB, creatinine, serum lactate, INR, HE

TB (< 15/15–25/ > 25 mg/dl; 1/2/3 points) + HE (0/I-II/III-IV; 1/2/3 points) + INR (< 1.8/1.8–2.5/ > 2.5; 1/2/3 points) + Lactate (< 1.5/1.5–2.5/ > 2.5 mmol/L;1/2/3 points) + creatinine (< 0.7/0.7–1.5/ > 1.5 mg/dl; 1/2/3 points)

Risk stratification: 28-day Mortality:

Grade-I (5–7): 13%;

Grade-II (8–10): 45%;

Grade-III (11–15): 86%

Predictive scores

CLIF-C ACLF-Ds

Acutely decompensated cirrhosis without ACLF

Age, ascites, WBC, albumin, TB, creatinine

0.03 × Age + 0.45 × Ascites + 0.26 × ln(WBC)–(0.37 × Albumin) + 0.57 × ln(TB) + 1.72 × ln(Creatinine) + 3 × 10

Predicting the onset of ACLF, but showed a similar accuracy to other scores

COSSH-onset- ACLFs

Acute deterioration of HBV-related chronic liver disease without ACLF

ALT, TB, INR, serum ferritin

0.101 × ln(ALT) + 0.819 × ln(TB) + 2.820 × ln(INR) + 0.016 × ln(ferritin)

Predicting the onset of HBV-ACLF at 7/14/28 days after admission;

Risk stratification for progression to ACLF at 7/14/28 days:

Low-risk (< 6.3): 2.5%/3.2%/3.7%;

High-risk (≥ 6.3): 42.6%/49.2%/50%